Alumis is using precision medicine to find effective treatment for patients with autoimmune disorders. Despite the advances made in treatments in the past decade, patients with autoimmune conditions continue to suffer. Using their precision analytics platform and exploration of immunologic diseases, Alumis is identifying autoimmune treatments that are right for each patient. The platform leverages high-quality curated genetic, clinical and health records data that is combined with the expertise of the Alumis team to identify the targets, pathways, indications and patient subsets they pursue. Alumis’ lead candidate, ESK-001, currently in clinical development for psoriasis with other indications soon to follow.

<p>Alumis is using precision medicine to find effective treatment for patients with autoimmune disorders. Despite the advances made in treatments in the past decade, patients with autoimmune conditions continue to suffer. Using their precision analytics platform and exploration of immunologic diseases, Alumis is identifying autoimmune treatments that are right for each patient. The platform leverages high-quality curated genetic, clinical and health records data that is combined with the expertise of the Alumis team to identify the targets, pathways, indications and patient subsets they pursue. Alumis’ lead candidate, ESK-001, currently in clinical development for psoriasis with other indications soon to follow.</p>


Alumis

Founded: 2021
Location: South SF, CA
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: Psoriasis
Drug types: IMM, DRM
Lead product: ESK-001
Funding: $200M B Jan 2022; $70M A May 2021

Drug notes:

About:

Jobs: